SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-14 and is reviewed periodically as new material appears.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
== Structure == Adenine forms several tautomers, compounds that can be rapidly interconverted and are often considered equivalent. However, in isolated conditions, i.e. in an inert gas matrix and in the gas phase, mainly the 9H-adenine tautomer is found.
The Somali Armed Forces (SAF) are the military forces of the Federal Republic of Somalia. Headed by the President as Commander in Chief, they are constitutionally mandated to ensure the nation's sovereignty, independence and territorial integrity. The SAF was initially made up of the Army, Navy, Air Force, Police Force and the National Security Service. In the post-independence period, it grew to become among the larger militaries on the continent. The subsequent outbreak of the civil war in 1991 led to the disbandment of the Somali National Army. In 2004, the gradual process of reconstituting the military was put in motion with the establishment of the Transitional Federal Government (TFG). The Somali Armed Forces are now overseen by the Ministry of Defence of the Federal Government of Somalia, formed in mid-2012. In January 2013, the Somali federal government also reopened the national intelligence service in Mogadishu, renaming the agency the National Intelligence and Security Agency (NISA). The Somaliland and Puntland regional governments maintain their own security and police forces.
Chipotle's menu consists of five items: burritos, bowls, tacos, quesadillas, and salads. The price of each item is based on the choice of chicken, pork carnitas, barbacoa, steak, tofu-based "sofritas", or vegetarian (with guacamole or queso, which would be at an extra charge otherwise). Additional optional toppings are offered free of charge, including: rice, beans, four types of salsa, fajita vegetables, sour cream, cheese, and lettuce. Although Chipotle styles itself as a "Mexican Grill", its menu is more accurately characterized as Cal-Mex, a form of Mexican-American cuisine with its roots in California. When asked in 2007 about expanding the menu, Steve Ells said, "[I]t's important to keep the menu focused, because if you just do a few things, you can ensure that you do them better than anybody else." Chipotle also offers a children's menu. Some restaurants sell beer and margaritas in addition to soft drinks and fruit drinks. The majority of food is prepared in each restaurant. Some exceptions are the beans and carnitas, which are prepared at a central kitchen in Chicago, Illinois. None of the restaurants have freezers, microwave ovens, or can openers. The chain experimented with breakfast foods at two airports in the Washington (D.C.) metropolitan area but decided against expanding the menu in that direction. Starting in 2009, selected restaurants had offered a pozole soup, which has since been discontinued. Starting in 2009, Chipotle tested a vegan chicken product (made by Gardein) called "Garden Blend" in various cities but discontinued it in 2010.
=== Discontinued === Balovaptan (RG-7314, RO-5028442, RO-5285119) – vasopressin V1A receptor antagonist Blarcamesine (AE-37, ANA001, ANAVEX 2-73) – sigma σ1, muscarinic acetylcholine M1, and ionotropic glutamate NMDA receptor agonist Brilaroxazine (RP-5063, RP-5000) – dopamine D2, D3, D4 receptor partial agonist, serotonin 5-HT1A receptor agonist, serotonin 5-HT2A, 5-HT2B, 5-HT7 receptor antagonist, and atypical antipsychotic Bumetanide oral liquid (S-95008) – sodium–potassium–chloride symporter/cotransporter inhibitor and indirect GABAergic inhibitor discontinued after failed phase 3 trial Carbetocin (CYP-2001) – oxytocin receptor agonist CX-516 (1-BCP; BDP-12, SPD-420; AMPAlex) – AMPA receptor modulator EM-036 (memantine analogue) – ionotropic glutamate NMDA receptor antagonist, other actions Fasoracetam (AEVI-001, LAM-105, MDGN-001, NFC-1, NS-105) – various actions and racetam Fluoxetine rapid-dissolve (AT-001; AT001; NPL-2008; Serelsa; Zydis™ ODT fluoxetine) – serotonin reuptake inhibitor GTS-21 (DMXB-A, DMXB-A sustained release, DMXB-A-SR) – α7 nicotinic acetylcholine receptor partial agonist Ketamine intranasal (RVT-701) – ionotropic glutamate NMDA receptor antagonist Memantine (Namenda) – ionotropic glutamate NMDA receptor antagonist, other actions Oxytocin intranasal (Syntocinon Nasal Spray; TUR 001) – oxytocin receptor agonist Research programme: AMPA receptor agonists (ampakines, AMPAkines; CX compounds) - RespireRx – ionotropic glutamate AMPA receptor agonists Research programme: NMDA receptor modulators - AbbVie/Naurex (NRX-1050; NRX-1051; NRX-1059; NRX-105x; NRX-1060; NRX-2085; NRX-20xx) – ionotropic glutamate NMDA receptor modulators Risperidone extended-release (Risperisphere) – dopamine D2 and D3 receptor antagonist, serotonin 5-HT1B, 5-HT2A, 5-HT2C, and 5-HT7 receptor antagonist or inverse agonist, α1- and α2-adrenergic receptor antagonist, histamine H1 receptor inverse agonist, and atypical antipsychotic Secretin (INN-329, RG-1068; SecreFlo) – medical imaging enhancer (diagnosis) Suramin (Antrypol) – DNA-directed DNA polymerase inhibitor and intercellular signaling peptide/protein inhibitor Trichuris suis ova (CNDO-201, TSO, TSO-2500, TSO-7500) – immunomodulator Trofinetide (Daybue; G-2Me-PE; Glycyl-2-methyl-L-prolyl-L-glutamic acid; NNZ-2566; IGF-1 (1–3) analogue) – unknown / various actions
Sources: en.wikipedia.org
== Early life and education == Otto Hahn was born in Frankfurt am Main on 8 March 1879, the youngest son of Heinrich Hahn, a prosperous glazier and founder of the Glasbau Hahn company, and Charlotte Hahn (née Giese). He had an older half-brother Karl, his mother's son from her previous marriage, and two older brothers, Heiner and Julius. The family lived above his father's workshop. The younger three boys were educated at the Klinger Oberrealschule in Frankfurt. At the age of 15, Otto began to take a special interest in chemistry, and carried out simple experiments in the laundry room of the family home. His father wanted him to study architecture, as he had built or acquired several residential and business properties, but Otto persuaded him that his ambition was to become an industrial chemist. In 1897, after passing his Abitur, Hahn began to study chemistry at Marburg University. His subsidiary subjects were mathematics, physics, mineralogy and philosophy. Hahn joined the Students' Association of Natural Sciences and Medicine, a student fraternity and a forerunner of today's Landsmannschaft Nibelungi (Coburger Convent der akademischen Landsmannschaften und Turnerschaften). He spent his third and fourth semesters at the Ludwig-Maximilians-Universität München, studying organic chemistry under Adolf von Baeyer, physical chemistry under Wilhelm Muthmann, and inorganic chemistry under Karl Andreas Hofmann. In 1901, Hahn received his doctorate at Marburg University for a dissertation entitled "On Bromine Derivates of Isoeugenol", a topic in classical organic chemistry.
Movement demands include strength, endurance and range of motion. Training oversights occurs when the body is overused. Internally, the joints, muscles, tendons, and ligaments can affect one's flexibility. As previously mentioned, each part of the body has its own limitations and combined, the range of motion can be affected. The mental attitude of the performer during the state of motion can also affect their range.
=== Hydration === As with other sports, weight trainers should avoid dehydration throughout the workout by drinking sufficient water. This is particularly true in hot environments, or for those older than 65. Some athletic trainers advise athletes to drink about 7 imperial fluid ounces (200 mL) every 15 minutes while exercising, and about 80 imperial fluid ounces (2.3 L) throughout the day. However, a much more accurate determination of how much fluid is necessary can be made by performing appropriate weight measurements before and after a typical exercise session, to determine how much fluid is lost during the workout. The greatest source of fluid loss during exercise is through perspiration, but as long as fluid intake is roughly equivalent to the rate of perspiration, hydration levels will be maintained. Under most circumstances, sports drinks do not offer a physiological benefit over water during weight training. However, under certain conditions—such as prolonged training sessions lasting over an hour, or when exercising in extremely hot and humid environments—sports drinks containing electrolytes and carbohydrates may help replenish lost salts and provide an energy boost. Ultimately, the ideal hydration approach depends on the individual's training intensity, duration, and personal needs. Insufficient hydration may cause lethargy, soreness or muscle cramps. The urine of well-hydrated persons should be nearly colorless, while an intense yellow color is normally a sign of insufficient hydration.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.